RSS

ovarian cancer

The NHS has approved an ovarian cancer treatment developed by a team of scientists at Newcastle University. Read more

News

A drug previously used to treat melanoma has been shown to offer improved treatment for women with a rare type of ovarian cancer compared to current therapies. Read more

News

A combination of drugs has offered promising results in an early clinical trial, where it has shrunk tumours in ovarian and lung cancer patients and prevented tumour growth for nearly six months. Read more

News

The European Medicines Agency (EMA) has approved AstraZeneca and Merck’s Lynparza (olaparib) tablets as maintenance therapy for the treatment of platinum-sensitive relapsed ovarian cancer, regardless of BRCA status. Read more

News

Ovarian cancer patients are losing out as funding and attention is focused on more prominent women’s diseases, says Australian oncology researcher, Dr Jim Coward, on World Ovarian Cancer Day (8 May). Read more

News

The Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the marketing authorisation of Lynparza (olaparib) tablets for patients with platinum-sensitive relapsed ovarian, fallopian tube, or primary perito Read more

News

Biotechnology company, GamaMabs Pharma, has received orphan drug designation from the US Food and Drug Administration (FDA) for its lead compound GM102 to treat advanced ovarian cancers. Read more

News

Biopharmaceutical company, Tesaro, has revealed that the European Commission has approved its monotherapy for the maintenance treatment of women with recurrent ovarian cancer. Read more

News

Small molecule pharmaceutical development and manufacturing capability and technology platform company, STA Pharmaceutical, has entered into a five-year supply agreement with oncology-focused biopharma company, TESARO. Read more

News

Voluntis and AstraZeneca have announced plans to test a digital support service for women undergoing treatment for recurrent platinum-sensitive high-grade ovarian cancer in clinical trials of cediranib plus olaparib Read more

News